Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis

BACKGROUND: Postoperative docetaxel plus S-1 (DS) chemotherapy is expected to be the standard therapeutic strategy for pStage III gastric cancer based on the results of the JACCRO GC-07 study. Neoadjuvant chemotherapy (NAC) is thought to have several advantages over adjuvant settings. OBJECTIVE: Thi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Surg Oncol
Glavni autori: Kano, Masayuki, Hayano, Koichi, Hayashi, Hideki, Hanari, Naoyuki, Gunji, Hisashi, Toyozumi, Takeshi, Murakami, Kentaro, Uesato, Masaya, Ota, Satoshi, Matsubara, Hisahiro
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2019
Teme:
Gastrointestinal Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510880/
https://ncbi.nlm.nih.gov/pubmed/30977014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-07299-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items